FDA lifts clinical hold on Filana’s simufilam for TSC-related epilepsy
TradingView News reports the FDA lifted the clinical hold on Filana’s simufilam for TSC-related epilepsy.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.
News Feed
2 results loaded, newest first. End of these results. The latest changes are still being indexed. Try again shortly for updated results.
FDA lifts clinical hold on simufilam IND; Phase 2a in TSC epilepsy
Filana Therapeutics said the FDA lifted the clinical hold on its IND for simufilam, enabling a planned Phase 2a study in TSC-related epilepsy, with screening expected to begin by Q1 2027.